2026 Q2 -tulosraportti
10 päivää sitten
‧32 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 3.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 6.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·6.8.We are not many Nordnet owners. It says 68! But what is your view on the future market for delcath. It's damn expensive treatment per Patient and as far as I can understand it is often only life-prolonging and not totally curative? And how many new cases of that type of cancer occur annually in usa and how large a part will one sacrifice resources on? They make a good business and have wild profit figures, but is it perhaps priced too much as if it is a growth rocket? I myself have 1000 shares and just sold 877 here on the jumpI'm not entirely sure I understand the business: They don't build clinics themselves, but sell the equipment to hospitals and have about 30 locations in the USA? But I'm thinking: there are probably no more than 2-400 patients who have been treated (many and continuous treatments) Approximately 800 new cases are registered annually and not all of them can be treated with their reading. I just think that if it's the equipment they profit from, then the pool will quickly be emptied. But they seem to profit from the equipment+chemo combination I need to read up a bit more on it. In Europe, their hardware has been used for many years for blood purification and in other types of cancer treatment. And I can definitely see a big breakthrough if they can use the blood purification to dose stronger and more effective chemo. I'll have a reading evening tomorrow. Good evening
6.8.Q2 earnings are out, looks positive to me. Top and bottom line beats while also raising revenue and gross margning guidance. 2026 revenue guidance increased to $104–108 million, up from "at least $100 million." Gross margin guidance raised to 86–89%, from 84–87%. Positive adjusted EBITDA guidance maintained. 31 active treatment centers, showing continued commercial expansion. “Our strong second quarter, including total revenue of $29.1 million and quarterly operating cash flow of $5.7 million, reflects continued momentum in HEPZATO procedures,” said Gerard Michel, Chief Executive Officer of Delcath Systems. “As we grow our active treatment center network and drive physician adoption, we are seeing increased usage of HEPZATO in combination with systemic therapies to treat metastatic uveal melanoma. The growing clinical experience with this treatment strategy is strengthening physician confidence in HEPZATO and supporting its development as a multi-indication, liver-directed therapy platform, including colorectal and breast cancer.”- 7.5.Q1 earnings are out, looks fine to me: Q1 Revenue 25.0 Million v expected 23.4 Q1 net loss 1.1 vs 1,6 expected Q1 GAAP EPS -0,04 v --0,08 - 0,10 expected 29 active centers 2026 FY outlook Revenue atleast 100 mil (this i quite modest to me) Gross margins 84-87% Positive adjusted EBITDA
- 6.4.This is very nice news for Delcaths Europe business. https://finance.yahoo.com/sectors/healthcare/articles/delcath-systems-inc-announces-inclusion-123000341.html
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
10 päivää sitten
‧32 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6.8.We are not many Nordnet owners. It says 68! But what is your view on the future market for delcath. It's damn expensive treatment per Patient and as far as I can understand it is often only life-prolonging and not totally curative? And how many new cases of that type of cancer occur annually in usa and how large a part will one sacrifice resources on? They make a good business and have wild profit figures, but is it perhaps priced too much as if it is a growth rocket? I myself have 1000 shares and just sold 877 here on the jumpI'm not entirely sure I understand the business: They don't build clinics themselves, but sell the equipment to hospitals and have about 30 locations in the USA? But I'm thinking: there are probably no more than 2-400 patients who have been treated (many and continuous treatments) Approximately 800 new cases are registered annually and not all of them can be treated with their reading. I just think that if it's the equipment they profit from, then the pool will quickly be emptied. But they seem to profit from the equipment+chemo combination I need to read up a bit more on it. In Europe, their hardware has been used for many years for blood purification and in other types of cancer treatment. And I can definitely see a big breakthrough if they can use the blood purification to dose stronger and more effective chemo. I'll have a reading evening tomorrow. Good evening
- 6.8.Q2 earnings are out, looks positive to me. Top and bottom line beats while also raising revenue and gross margning guidance. 2026 revenue guidance increased to $104–108 million, up from "at least $100 million." Gross margin guidance raised to 86–89%, from 84–87%. Positive adjusted EBITDA guidance maintained. 31 active treatment centers, showing continued commercial expansion. “Our strong second quarter, including total revenue of $29.1 million and quarterly operating cash flow of $5.7 million, reflects continued momentum in HEPZATO procedures,” said Gerard Michel, Chief Executive Officer of Delcath Systems. “As we grow our active treatment center network and drive physician adoption, we are seeing increased usage of HEPZATO in combination with systemic therapies to treat metastatic uveal melanoma. The growing clinical experience with this treatment strategy is strengthening physician confidence in HEPZATO and supporting its development as a multi-indication, liver-directed therapy platform, including colorectal and breast cancer.”
- 7.5.Q1 earnings are out, looks fine to me: Q1 Revenue 25.0 Million v expected 23.4 Q1 net loss 1.1 vs 1,6 expected Q1 GAAP EPS -0,04 v --0,08 - 0,10 expected 29 active centers 2026 FY outlook Revenue atleast 100 mil (this i quite modest to me) Gross margins 84-87% Positive adjusted EBITDA
- 6.4.This is very nice news for Delcaths Europe business. https://finance.yahoo.com/sectors/healthcare/articles/delcath-systems-inc-announces-inclusion-123000341.html
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 3.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 6.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2026 Q2 -tulosraportti
10 päivää sitten
‧32 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 3.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 6.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6.8.We are not many Nordnet owners. It says 68! But what is your view on the future market for delcath. It's damn expensive treatment per Patient and as far as I can understand it is often only life-prolonging and not totally curative? And how many new cases of that type of cancer occur annually in usa and how large a part will one sacrifice resources on? They make a good business and have wild profit figures, but is it perhaps priced too much as if it is a growth rocket? I myself have 1000 shares and just sold 877 here on the jumpI'm not entirely sure I understand the business: They don't build clinics themselves, but sell the equipment to hospitals and have about 30 locations in the USA? But I'm thinking: there are probably no more than 2-400 patients who have been treated (many and continuous treatments) Approximately 800 new cases are registered annually and not all of them can be treated with their reading. I just think that if it's the equipment they profit from, then the pool will quickly be emptied. But they seem to profit from the equipment+chemo combination I need to read up a bit more on it. In Europe, their hardware has been used for many years for blood purification and in other types of cancer treatment. And I can definitely see a big breakthrough if they can use the blood purification to dose stronger and more effective chemo. I'll have a reading evening tomorrow. Good evening
- 6.8.Q2 earnings are out, looks positive to me. Top and bottom line beats while also raising revenue and gross margning guidance. 2026 revenue guidance increased to $104–108 million, up from "at least $100 million." Gross margin guidance raised to 86–89%, from 84–87%. Positive adjusted EBITDA guidance maintained. 31 active treatment centers, showing continued commercial expansion. “Our strong second quarter, including total revenue of $29.1 million and quarterly operating cash flow of $5.7 million, reflects continued momentum in HEPZATO procedures,” said Gerard Michel, Chief Executive Officer of Delcath Systems. “As we grow our active treatment center network and drive physician adoption, we are seeing increased usage of HEPZATO in combination with systemic therapies to treat metastatic uveal melanoma. The growing clinical experience with this treatment strategy is strengthening physician confidence in HEPZATO and supporting its development as a multi-indication, liver-directed therapy platform, including colorectal and breast cancer.”
- 7.5.Q1 earnings are out, looks fine to me: Q1 Revenue 25.0 Million v expected 23.4 Q1 net loss 1.1 vs 1,6 expected Q1 GAAP EPS -0,04 v --0,08 - 0,10 expected 29 active centers 2026 FY outlook Revenue atleast 100 mil (this i quite modest to me) Gross margins 84-87% Positive adjusted EBITDA
- 6.4.This is very nice news for Delcaths Europe business. https://finance.yahoo.com/sectors/healthcare/articles/delcath-systems-inc-announces-inclusion-123000341.html
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt